Sapient Saliva Protein Assays

Sapient’s mass spectrometry-based saliva protein assays offer an in-depth approach to non-invasively probe systemic health and enable decentralized clinical trials, enabling efficient measure of biomarkers of early disease pathology and drug response within the human salivary proteome. With the ability to capture both host-derived and microbiome-derived proteins, our saliva proteomics workflows are ideal for non-invasive measure of biological activity and drug targets, as well as for non-invasive drug response monitoring.

These assays can be used to measure a single or multiple proteins across more than 6,000+ protein groups, comprising ~37,600 peptides, in less than 20 µl of saliva (Figure 1). This comprises proteins intrinsic to saliva as well as those in central circulation which permeate the salivary glands, including free proteins and exosomal and membrane-bound proteins released from various tissue beds. In addition, Sapient’s mass spectrometry workflows enable capture of established and novel post-translational modifications (PTMs) on proteins.

Importantly, Sapient’s saliva protein assays can measure greater than 800 known and emerging drug targets, inclusive of 260 proteins targets for approved therapeutic agents. This provides for non-invasive measure of key pharmacokinetic (PK) and pharmacodynamic (PD) metrics as part of dose escalation and therapeutic clinical trials.